Situation of the Prescription service

Situation of the Prescription service

The situation of the joint testing of the Prescription service is compiled on this page. Tabulating starts from joint tests completed on 29 April 2016.

Read more about the requirements for taking part in joint testing on the Kanta Services website:

Ongoing joint testings

No ongoing joint testings

Table: Abilita Hälsovård / Abilita Oy Ab accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information

20102016 / 30.12.2016

Functionality for action on behalf of a minor

20072020 / 14.9.2020

Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database 20122022 / 8.2.2022

Ongoing joint testings

No ongoing joint testings

Table: Acute / Vitec Acute Oy accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information 20012016 / 30.11.2016
​​Forward compatibility of the functionality to act on behalf of a minor

- / 17.2.2020

Functionality for action on behalf of a minor 20072021 / 14.9.2021
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database 20032022 / 3.2.2022
Table: AssisDent / Entteri Professional Software Oy ongoing joint testings
Ongoing joint testings Registration, return date of pre-test cases Testing between system supplier and Kela Testing between client test organisation and Kela Cross-testing
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database 10.11.2021 Ongoing, 16.11.2021 Not tested Not tested
Table: AssisDent / Entteri Professional Software Oy accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information

20062016 / 27.12.2016

​Forward compatibility of the functionality to act on behalf of a minor

- / 14.9.2020

Functionality for action on behalf of a minor 20062021 / 30.6.2021

 

Table: DomaCare / Invian Oy ongoing joint testings
Ongoing joint testings Registration, return date of pre-test cases Testing between system supplier and Kela Testing between client test organisation and Kela Cross-testing
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database 25.2.2022 ​Ongoing, 28.2.2022 Not tested Not tested
Table: DomaCare / Invian Oy accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9

20142017 / 14.3.2017

Functionality for action on behalf of a minor 20032021 / 4.5.2021
Refusal to share prescription information 20052021 / 29.6.2021

Ongoing joint testings

No ongoing joint testings

Table: DynamicHealth / TietoEVRY Oyj accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information

20032016 / 30.12.2016

 

​Forward compatibility of the functionality to act on behalf of a minor

- / 12.3.2020

Functionality for action on behalf of a minor

20122020 / 20.11.2020

Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database 20022022 / 2.2.2022

Ongoing joint testings

No ongoing joint testings

Table: Effica / TietoEVRY Oyj accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information

20032016 / 9.12.2016

Table: Epic / Epic Helsinki Oy ongoing joint testings
Ongoing joint testings Registration, return date of pre-test cases Testing between system supplier and Kela Testing between client test organisation and Kela Cross-testing
Functionality for action on behalf of a minor 9.9.2021 ​Ongoing, 30.9.2021 Not tested Not tested
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database 10.12.2021 ​Ongoing, 14.12.2021 Not tested Not tested
Table: Epic / Epic Helsinki Oy accepted joint testing
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.42 and requirement specifications 2.9, Refusal to share prescription information

20022018 / 5.10.2018

Forward compatibility of the functionality to act on behalf of a minor

- / 7.9.2020

Ongoing joint testings

No ongoing joint testings

Table: eRA / Atostek Oy accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information

20092016 / 29.12.2016

​​Functionality for action on behalf of a minor

20032020 / 16.3.2020

​Functionality for action on behalf of a minor (testing of system changes)

20052020 / 10.8.2020

The ​2022 version of the Pharmaceutical Database 20102022 / 11.4.2022
​Structured dosage 20112022 / 12.4.2022
FHIR interface to search for identifiers 20082022 / 22.3.2022
Table: ESKO / Esko Systems Oy ongoing joint testings
Ongoing joint testings Registration, return date of pre-test cases Testing between system supplier and Kela Testing between client test organisation and Kela Cross-testing
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database  21.12.2021 Ongoing,     
Table: ESKO / Esko Systems Oy accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information

20022016 / 9.12.2016

​​Forward compatibility of the functionality to act on behalf of a minor

- / 7.5.2020

Functionality for action on behalf of a minor 20012022 / 31.1.2022

Ongoing joint testings

No ongoing joint testings

Table: GFS / CGI Oy accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information

- / 25.11.2016

​Forward compatibility of the functionality to act on behalf of a minor

- / 6.2.2020

Functionality for action on behalf of a minor

20082020 / 22.9.2020

Table: Hilkka / FastROI Oy ongoing joint testings
Ongoing joint testings Registration, return date of pre-test cases Testing between system supplier and Kela Testing between client test organisation and Kela Cross-testing
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database 9.2.2022 Ongoing, 10.2.2022 Not tested Not tested
Table: Hilkka / FastROI Oy a joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9

20082016 / 30.12.2016

Refusal to share prescription information

20012018 / 11.1.2018

​​Forward compatibility of the functionality to act on behalf of a minor

- / 16.4.2020

Functionality for action on behalf of a minor 20022021 / 12.4.2021

Ongoing joint testings

No ongoing joint testings

Table: Kelain / Kela accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9   

20042016 / 13.12.2016

Refusal to share prescription information

20202017 / 1.6.2017

Functionality for action on behalf of a minor

20012020 / 14.1.2020

Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database 20042022 / 3.2.2022

Ongoing joint testings

No ongoing joint testings

Table: Lifecare / TietoEVRY Oyj accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information

20192017 / 11.5.2017

​Forward compatibility of the functionality to act on behalf of a minor

- / 14.2.2020

Functionality for action on behalf of a minor 18.11.2021 / 20102021
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database 20062022 / 23.2.2022
Table: MAXX / Receptum Oy ongoing joint testings
Ongoing joint testings Registration, return date of pre-test cases Testing between system supplier and Kela Testing between client test organisation and Kela Cross-testing
The ​2022 version of the Pharmaceutical Database 25.11.2021 Ongoing, 14.11.2021 Not tested Not tested
​Structured dosage 25.11.2021 Ongoing, 14.1.2022 Not tested Not tested
Table: MAXX / Receptum Oy accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information

20122017 / 11.1.2017

Cross-border prescription

20012019 / 30.9.2019

Functionality for action on behalf of a minor

20062020 / 8.9.2020

Table: Mediatri / Mediconsult Oy ongoing joint testings
Ongoing joint testings Registration, return date of pre-test cases Testing between system supplier and Kela Testing between client test organisation and Kela Cross-testing
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database 14.9.2021 Ongoing, 22.9.2021 Not tested Not tested
Table: Mediatri / Mediconsult Oy accepted joint testings
Accepted joint testings Statement number and date

Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9

20072016 / 30.12.2016

Refusal to share prescription information

20212017 / 5.6.2017

Forward compatibility of the functionality to act on behalf of a minor

- / 5.5.2020

 

Functionality for action on behalf of a minor   

20042020 / 8.10.2020

Table: Mediresepti / Mediconsult Oy ongoing joint testings
Ongoing joint testings Registration, return date of pre-test cases Testing between system supplier and Kela Testing between client test organisation and Kela Cross-testing
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database 14.9.2021 Ongoing, 22.9.2021 Not tested Not tested
Table: Mediresepti / Mediconsult Oy accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9

20132016 / 30.12.2016

Refusal to share prescription information

20222017 / 4.12.2017

​Forward compatibility of the functionality to act on behalf of a minor

- / 8.5.2020

Functionality for action on behalf of a minor

20132020 / 26.11.2020

Ongoing joint testings

No ongoing joint testings

Table: Navitas / Elisa Appelsiini Oy accepted joint testings
Accepted joint testings Statement number and date
Refusal to share prescription information   

20182017 / 24.2.2017

Table: pd3 / Pharmadata Oy ongoing joint testings
Ongoing joint testings Registration, return date of pre-test cases Testing between system supplier and Kela Testing between client test organisation and Kela Cross-testing
Structured dosage 5.4.2022 Ongoing, 11.4.2022 Not tested Not tested
The ​2022 version of the Pharmaceutical Database​ 12.4.2022 Ongoing, 21.4.2022 Not tested Not tested
Table: pd3 / Pharmadata Oy accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information

20172017 / 27.1.2017

Cross-border prescription

20022020 / 20.2.2020

Functionality for action on behalf of a minor

20102020 / 24.9.2020

Ongoing joint testings

No ongoing joint testings

Table: Pegasos / CGI Oy accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information

20052016 / 20.12.2016

​Forward compatibility of the functionality to act on behalf of a minor

- / 8.4.2020

Functionality for action on behalf of a minor (OMNI360 Kertomus)

20012021 / 21.1.2021

Functionality for action on behalf of a minor 20082021 / 14.9.2021
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database (OMNI360 Kertomus) 20122021 / 18.11.2021
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database 20052022 / 24.2.2022
Table: Salix / Pharmadata Oy ongoing joint testings
Ongoing joint testings Registration, return date of pre-test cases Testing between system supplier and Kela Testing between client test organisation and Kela Cross-testing
​Structured dosage 16.2.2022 ​Ongoing, 23.2.2022 Not tested Not tested
The ​2022 version of the Pharmaceutical Database 17.2.2022 ​Ongoing, 25.3.2022 Not tested Not tested
Table: Salix / Pharmadata Oy accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information

20162017 / 27.1.2017

Cross-border prescription

20022019 / 10.12.2019

Functionality for action on behalf of a minor

20092020 / 24.9.2020

Table: SoftMedic / CGI Oy ongoing joint testings
Ongoing joint testings Registration, return date of pre-test cases Testing between system supplier and Kela Testing between client test organisation and Kela Cross-testing
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database 9.2.2022 Ongoing, 15.2.2022 Not tested Not tested
Table: SoftMedic / CGI Oy accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information

- / 22.11.2016

Forward compatibility of the functionality to act on behalf of a minor

- / 10.9.2020

Functionality for action on behalf of a minor 20092021 / 11.10.2021

Ongoing joint testings

No ongoing joint testings

Table: Uranus / CGI Oy accepted joint testings
Accepted joint testings Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information

20152017 / 11.1.2017

 

​Forward compatibility of the functionality to act on behalf of a minor

- / 14.1.2020

Functionality for action on behalf of a minor 20042021 / 16.6.2021
​​Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database 20112021 / 18.11.2021
Last updated 03.06.2021